MicroRNA‑30a suppresses papillary thyroid cancer cell proliferation, migration and invasion by directly targeting E2F7

Guo,Haiyan; Zhang,Linyun

doi:10.3892/etm.2019.7532

MicroRNA‑30a suppresses papillary thyroid cancer cell proliferation, migration and invasion by directly targeting E2F7

Authors:
- Haiyan Guo
- Linyun Zhang
View Affiliations

Affiliations: Department of Clinical Medicine, Fenyang College, Shanxi Medical University, Fenyang, Shanxi 032200, P.R. China, Shanxi Fenyang Prison Hospital, Fenyang, Shanxi 032200, P.R. China
Published online on: April 30, 2019 https://doi.org/10.3892/etm.2019.7532
Pages: 209-215
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNA (miRNA/miR)‑30a, a tumor‑associated miRNA, has been implicated in the tumorigenesis and progression of different types of human cancer. Thyroid cancer is a common endocrine malignancy, of which papillary thyroid cancer (PTC) accounts for ~80‑90% of all TC. However, the effect of miR‑30a in PTC is yet to be fully elucidated. The TPC‑1 human PTC cell line, as well as the normal human thyroid cell line (HT‑ori3), were utilized in the current study. The PTC cell line was transfected with a miR‑30a mimic. Subsequently, reverse transcription‑quantitative polymerase chain reaction was performed to detect the expression of miR‑30a and E2F transcription factor 7 (E2F7). Cell proliferation was assessed via a MTT assay and transwell migration and invasion assays were performed to detect the migration and invasion of PTC cells. A dual‑luciferase reporter assay was also utilized to clarify the association between miR‑30a and E2F7. The results of the current study revealed that miR‑30a was significantly downregulated in TPC‑1 cells compared with HT‑ori3 cells and that the expression of E2F7 was significantly upregulated in PTC cells. The upregulation of miR‑30a also inhibited the proliferation, migration and invasion of PTC cells. Furthermore, the luciferase assay revealed that miR‑30a binds to the 3'‑UTR of E2F7. Additionally, the overexpression of miR‑30a decreased E2F7 levels in TPC‑1 cells. These results indicate that miR‑30a functions as a tumor suppressor in PTC by direct targeting E2F7 and that miR‑30a may be a novel therapeutic target for patients with PTC.

View Figures

View References

1	Wang J, Yang H, Si Y, Hu D, Yu Y, Zhang Y, Gao M and Zhang H: Iodine promotes tumorigenesis of thyroid cancer by suppressing Mir-422a and up-regulating MAPK1. Cell Physiol Biochem. 43:1325–1336. 2017. View Article : Google Scholar : PubMed/NCBI
2	Kaptan E, Sancar-Bas S, Sancakli A, Bektas S and Bolkent S: The effect of plant lectins on the survival and malignant behaviors of thyroid cancer cells. J Cell Biochem. 119:6274–6287. 2018. View Article : Google Scholar : PubMed/NCBI
3	Sokić SI, Adanja BJ, Vlajinac HD, Janković RR, Marinković JP and Zivaljević VR: Risk factors for thyroid cancer. Neoplasma. 41:371–374. 1994.PubMed/NCBI
4	Takacsova E, Kralik R, Waczulikova I, Zavodna K and Kausitz J: A different prognostic value of BRAFV600E mutation positivity in various age groups of patients with papillary thyroid cancer. Neoplasma. 64:156–164. 2017. View Article : Google Scholar : PubMed/NCBI
5	Di W, Li Q, Shen W, Guo H and Zhao S: The long non-coding RNA HOTAIR promotes thyroid cancer cell growth, invasion and migration through the miR-1-CCND2 axis. Am J Cancer Res. 7:1298–1309. 2017.PubMed/NCBI
6	Xing M, Haugen BR and Schlumberger M: Progress in molecular-based management of differentiated thyroid cancer. Lancet. 381:1058–1069. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ding ZY, Huang YJ, Tang JD, Li G, Jiang PQ and Wu HT: Silencing of hypoxia-inducible factor-1α promotes thyroid cancer cell apoptosis and inhibits invasion by downregulating WWP2, WWP9, VEGF and VEGFR2. Exp Ther Med. 12:3735–3741. 2016. View Article : Google Scholar : PubMed/NCBI
8	Lim ST, Jeon YW and Suh YJ: The prognostic values of preoperative tumor volume and tumor diameter in T1N0 papillary thyroid cancer. Cancer Res Treat. 49:890–897. 2017. View Article : Google Scholar : PubMed/NCBI
9	Rachinsky I, Rajaraman M, Leslie WD, Zahedi A, Jefford C, McGibbon A, Young JE, Pathak KA, Badreddine M, De Brabandere S, et al: Regional variation across Canadian centers in radioiodine administration for thyroid remnant ablation in well-differentiated thyroid cancer diagnosed in 2000–2010. J Thyroid Res. 2016:28679162016. View Article : Google Scholar : PubMed/NCBI
10	Guan H, Liang W, Xie Z, Li H, Liu J, Liu L, Xiu L and Li Y: Down-regulation of miR-144 promotes thyroid cancer cell invasion by targeting ZEB1 and ZEB2. Endocrine. 48:566–574. 2015. View Article : Google Scholar : PubMed/NCBI
11	Vasko VV and Saji M: Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis. Curr Opin Oncol. 19:11–17. 2007. View Article : Google Scholar : PubMed/NCBI
12	Liao T, Wang YJ, Hu JQ, Wang Y, Han LT, Ma B, Shi RL, Qu N, Wei WJ, Guan Q, et al: Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer in vitro. Oncol Rep. 39:2185–2192. 2018.PubMed/NCBI
13	Lu ZL, Chen YJ, Jing XY, Wang NN, Zhang T and Hu CJ: Detection and identification of serum peptides biomarker in papillary thyroid cancer. Med Sci Monit. 24:1581–1587. 2018. View Article : Google Scholar : PubMed/NCBI
14	Zhao W, Chen S, Hou X, Chen G and Zhao Y: CHK2 promotes anoikis and is associated with the progression of papillary thyroid cancer. Cell Physiol Biochem. 45:1590–1602. 2018. View Article : Google Scholar : PubMed/NCBI
15	Shi Z, Zhou H, Lu L, Li X, Fu Z, Liu J, Kang Y, Wei Z, Pan B, Liu L, et al: The roles of microRNAs in spinal cord injury. Int J Neurosci. 127:1104–1115. 2017. View Article : Google Scholar : PubMed/NCBI
16	Ouyang Q, Xu L, Cui H, Xu M and Yi L: MicroRNAs and cell cycle of malignant glioma. Int J Neurosci. 126:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
17	Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
18	Wang RJ, Zheng YH, Wang P and Zhang JZ: Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol. 8:765–771. 2015.PubMed/NCBI
19	Fuziwara CS and Kimura ET: MicroRNA deregulation in anaplastic thyroid cancer biology. Int J Endocrinol. 2014:7434502014. View Article : Google Scholar : PubMed/NCBI
20	Costa-Pinheiro P, Ramalho-Carvalho J, Vieira FQ, Torres-Ferreira J, Oliveira J, Gonçalves CS, Costa BM, Henrique R and Jerónimo C: MicroRNA-375 plays a dual role in prostate carcinogenesis. Clin Epigenetics. 7:422015. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Xing M: Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013. View Article : Google Scholar : PubMed/NCBI
23	Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, Gilbert J, Harrison B, Johnson SJ, Giles TE, et al: Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 81 (Suppl 1):S1–S122. 2014. View Article : Google Scholar
24	Bi CL, Zhang YQ, Li B, Guo M and Fu YL: MicroRNA-520a-3p suppresses epithelial-mesenchymal transition, invasion, and migration of papillary thyroid carcinoma cells via the JAK1-mediated JAK/STAT signaling pathway. J Cell Physiol. 234:4054–4067. 2019. View Article : Google Scholar : PubMed/NCBI
25	Liu H, Guo J, Chai H and Meng X: MicroRNA-744 suppresses cell proliferation and invasion of papillary thyroid cancer by directly targeting NOB1. Mol Med Rep. 19:1903–1910. 2019.PubMed/NCBI
26	Heidari Z, Mohammadpour-Gharehbagh A, Eskandari M, Harati-Sadegh M and Salimi S: Genetic polymorphisms of miRNA let7a-2 and pri-mir-34b/c are associated with an increased risk of papillary thyroid carcinoma and clinical/pathological features. J Cell Biochem. 14–Dec;2018.(Epub ahead of print).
27	Damodaran M, Paul SFD and Venkatesan V: Genetic polymorphisms in miR-146a, miR-196a2 and miR-125a genes and its association in prostate cancer. Pathol Oncol Res. 29–Mar;2018.(Epub ahead of print). View Article : Google Scholar
28	Mo JS, Park YR and Chae SC: MicroRNA 196B regulates HOXA5, HOXB6 and GLTP expression levels in colorectal cancer cells. Pathol Oncol Res. 12–Mar;2018.(Epub ahead of print). View Article : Google Scholar
29	Seclaman E, Narita D, Anghel A, Cireap N, Ilina R, Sirbu IO and Marian C: MicroRNA expression in laser micro-dissected breast cancer tissue samples-a pilot study. Pathol Oncol Res. 25:233–239. 2019. View Article : Google Scholar
30	Yue K, Wang X, Wu Y, Zhou X, He Q and Duan Y: microRNA-7 regulates cell growth, migration and invasion via direct targeting of PAK1 in thyroid cancer. Mol Med Rep. 14:2127–2134. 2016. View Article : Google Scholar : PubMed/NCBI
31	Dong S, Meng X, Xue S, Yan Z, Ren P and Liu J: microRNA-141 inhibits thyroid cancer cell growth and metastasis by targeting insulin receptor substrate 2. Am J Transl Res. 8:1471–1481. 2016.PubMed/NCBI
32	Wang P, Meng X, Huang Y, Lv Z, Liu J, Wang G, Meng W, Xue S, Zhang Q, Zhang P and Chen G: MicroRNA-497 inhibits thyroid cancer tumor growth and invasion by suppressing BDNF. Oncotarget. 8:2825–2834. 2017.PubMed/NCBI
33	Westendorp B, Mokry M, Groot Koerkamp MJ, Holstege FC, Cuppen E and de Bruin A: E2F7 represses a network of oscillating cell cycle genes to control S-phase progression. Nucleic Acids Res. 40:3511–3523. 2012. View Article : Google Scholar : PubMed/NCBI
34	Chen D, Pacal M, Wenzel P, Knoepfler PS, Leone G and Bremner R: Division and apoptosis of E2f-deficient retinal progenitors. Nature. 462:925–929. 2009. View Article : Google Scholar : PubMed/NCBI
35	Mitxelena J, Apraiz A, Vallejo-Rodríguez J, García-Santisteban I, Fullaondo A, Alvarez-Fernández M, Malumbres M and Zubiaga AM: An E2F7-dependent transcriptional program modulates DNA damage repair and genomic stability. Nucleic Acids Res. 46:4546–4559. 2018. View Article : Google Scholar : PubMed/NCBI
36	Carvajal LA, Hamard PJ, Tonnessen C and Manfredi JJ: E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression. Genes Dev. 26:1533–1545. 2012. View Article : Google Scholar : PubMed/NCBI
37	Yin W, Wang B, Ding M, Huo Y, Hu H, Cai R, Zhou T, Gao Z, Wang Z and Chen D: Elevated E2F7 expression predicts poor prognosis in human patients with gliomas. J Clin Neurosci. 33:187–193. 2016. View Article : Google Scholar : PubMed/NCBI
38	Ye YY, Mei JW, Xiang SS, Li HF, Ma Q, Song XL, Wang Z, Zhang YC, Liu YC, Jin YP, et al: MicroRNA-30a-5p inhibits gallbladder cancer cell proliferation, migration and metastasis by targeting E2F7. Cell Death Dis. 9:4102018. View Article : Google Scholar : PubMed/NCBI